Neuberger Berman High Yield Strategies Fund (NYSEAMERICAN:NHS) Shares Pass Below 200-Day Moving Average - Time to Sell?

Key Points

• NHS crossed below its 200-day moving average, trading as low as $6.52 and last at $6.55 versus a 200-day MA of $7.31 on volume of 396,628, a potential technical bearish signal.
• The fund declared a monthly dividend of $0.0905 per share payable April 30 (ex‑dividend/record date April 7), implying an annualized yield of about 16.6%.
• Several institutional investors increased their stakes in the fourth quarter—most notably Guggenheim (now 567,943 shares)—indicating continued institutional interest despite the price weakness.

Neuberger Berman High Yield Strategies Fund (NYSEAMERICAN:NHS - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $7.31 and traded as low as $6.52. Neuberger Berman High Yield Strategies Fund shares last traded at $6.55, with a volume of 396,628 shares.

Neuberger Berman High Yield Strategies Fund Trading Up 0.3%

The stock's 50-day moving average is $7.22 and its two-hundred day moving average is $7.31.

Neuberger Berman High Yield Strategies Fund Announces Dividend

The business also recently disclosed a monthly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, April 7th will be given a dividend of $0.0905 per share. The ex-dividend date of this dividend is Tuesday, April 7th. This represents a c) dividend on an annualized basis and a dividend yield of 16.6%.

Hedge Funds Weigh In On Neuberger Berman High Yield Strategies Fund

A number of hedge funds have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV boosted its position in shares of Neuberger Berman High Yield Strategies Fund by 24.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,244 shares of the investment management company's stock worth $99,000 after purchasing an additional 2,597 shares during the period. Guggenheim Capital LLC boosted its position in shares of Neuberger Berman High Yield Strategies Fund by 38.0% during the 4th quarter. Guggenheim Capital LLC now owns 567,943 shares of the investment management company's stock worth $4,225,000 after purchasing an additional 156,386 shares during the period. Cetera Investment Advisers boosted its position in shares of Neuberger Berman High Yield Strategies Fund by 232.1% during the 4th quarter. Cetera Investment Advisers now owns 36,883 shares of the investment management company's stock worth $274,000 after purchasing an additional 25,777 shares during the period. Osaic Holdings Inc. lifted its holdings in Neuberger Berman High Yield Strategies Fund by 86.2% during the 4th quarter. Osaic Holdings Inc. now owns 74,294 shares of the investment management company's stock worth $553,000 after buying an additional 34,387 shares in the last quarter. Finally, Kestra Advisory Services LLC lifted its holdings in Neuberger Berman High Yield Strategies Fund by 18.0% during the 4th quarter. Kestra Advisory Services LLC now owns 18,728 shares of the investment management company's stock worth $139,000 after buying an additional 2,857 shares in the last quarter.

Neuberger Berman High Yield Strategies Fund Company Profile

The Neuberger Berman High Yield Strategies Fund (NYSE American: NHS) is a closed-end, fixed-income management investment company focused on delivering high current income with the potential for capital appreciation. The fund primarily invests in below-investment-grade corporate debt—often referred to as high-yield bonds—issued by U.S. and select non-U.S. issuers. Through a diversified portfolio of high-yield instruments, NHS aims to provide enhanced yield relative to investment-grade alternatives.

Under its investment policy, NHS allocates the majority of its assets to corporate securities spanning sectors such as communications, energy, consumer goods, and industrials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.